1. Home
  2. MAZE vs SCM Comparison

MAZE vs SCM Comparison

Compare MAZE & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAZE
  • SCM
  • Stock Information
  • Founded
  • MAZE 2018
  • SCM 2012
  • Country
  • MAZE United States
  • SCM United States
  • Employees
  • MAZE N/A
  • SCM N/A
  • Industry
  • MAZE
  • SCM Finance/Investors Services
  • Sector
  • MAZE
  • SCM Finance
  • Exchange
  • MAZE NYSE
  • SCM Nasdaq
  • Market Cap
  • MAZE 367.0M
  • SCM 392.4M
  • IPO Year
  • MAZE 2025
  • SCM 2012
  • Fundamental
  • Price
  • MAZE $11.13
  • SCM $13.84
  • Analyst Decision
  • MAZE Strong Buy
  • SCM Hold
  • Analyst Count
  • MAZE 3
  • SCM 1
  • Target Price
  • MAZE $25.67
  • SCM $13.00
  • AVG Volume (30 Days)
  • MAZE 100.1K
  • SCM 112.6K
  • Earning Date
  • MAZE 08-14-2025
  • SCM 08-06-2025
  • Dividend Yield
  • MAZE N/A
  • SCM 11.64%
  • EPS Growth
  • MAZE N/A
  • SCM 26.74
  • EPS
  • MAZE 0.34
  • SCM 1.42
  • Revenue
  • MAZE $167,500,000.00
  • SCM $103,691,042.00
  • Revenue This Year
  • MAZE N/A
  • SCM $0.36
  • Revenue Next Year
  • MAZE N/A
  • SCM $2.94
  • P/E Ratio
  • MAZE $30.79
  • SCM $9.65
  • Revenue Growth
  • MAZE N/A
  • SCM N/A
  • 52 Week Low
  • MAZE $6.71
  • SCM $11.19
  • 52 Week High
  • MAZE $17.00
  • SCM $15.56
  • Technical
  • Relative Strength Index (RSI)
  • MAZE N/A
  • SCM 57.06
  • Support Level
  • MAZE N/A
  • SCM $13.48
  • Resistance Level
  • MAZE N/A
  • SCM $13.89
  • Average True Range (ATR)
  • MAZE 0.00
  • SCM 0.23
  • MACD
  • MAZE 0.00
  • SCM 0.01
  • Stochastic Oscillator
  • MAZE 0.00
  • SCM 83.65

About MAZE MAZE THERAPEUTICS INC

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

Share on Social Networks: